Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: A scientific statement from the American Heart Association and the American Diabetes Association

Circulation

Volumn 132, Issue 8, 2015, Pages 691-718

  Fox, Caroline S ^a   Golden, Sherita Hill ^a   Anderson, Cheryl ^a   Bray, George A ^a   Burke, Lora E ^a   De Boer, Ian H ^a   Deedwania, Prakash ^a   Eckel, Robert H ^a   Ershow, Abby G ^a   Fradkin, Judith ^a   Inzucchi, Silvio E ^a   Kosiborod, Mikhail ^a   Nelson, Robert G ^a   Patel, Mahesh J ^a   Pignone, Michael ^a   Quinn, Laurie ^a   Schauer, Philip R ^a   Selvin, Elizabeth ^a   Vafiadis, Dorothea K ^a  

^a NONE

Author keywords

AHA Scientific Statements; cardiovascular disease; diabetes; primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BARIATRIC SURGERY; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LIGHT; MEDICAL SOCIETY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; OBESITY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; SCREENING; WEIGHT CONTROL; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STANDARDS; TRENDS; UNITED STATES;

AMERICAN HEART ASSOCIATION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; UNITED STATES;

EID: 84940706705     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000230     Document Type: Article

References (232)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013 127 143 152. doi: 10.1161/CIR.0b013e318282ab8f
2. Diabetes mellitus: a major risk factor for cardiovascular disease: a joint editorial statement by the American Diabetes Association; the National Heart, Lung, and Blood Institute; the Juvenile Diabetes Foundation International; the National Institute of Diabetes and Digestive and Kidney Diseases; and the American Heart Association. Circulation 1999 100 1132 1133
3. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ, Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007 115 114 126. doi: 10.1161/CIRCULATIONAHA.106.179294
4. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(suppl 1):S1-S89
5. Cheng YJ, Imperatore G, Geiss LS, Wang J, Saydah SH, Cowie CC, Gregg EW., Secular changes in the age-specific prevalence of diabetes among U.S. adults: 1988-2010. Diabetes Care 2013 36 2690 2696. doi: 10.2337/dc12-2074
6. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW., Achievement of goals in U.S. diabetes care, 1999-2010 [published correction appears in N Engl J Med. 2013;369:587]. N Engl J Med 2013 368 1613 1624. doi: 10.1056/NEJMsa1213829
7. Deleted in proof
8. The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 329 977 986
9. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M., Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 28 103 117
10. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet. 1998;352:1558]. Lancet 1998 352 854 865
11. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K, DETECT-2 Collaboration Writing Group Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes [published correction appears in Diabetes Care. 2011;34:1888]. Diabetes Care 2011 34 145 150. doi: 10.2337/dc10-1206
12. Cheng YJ, Gregg EW, Geiss LS, Imperatore G, Williams DE, Zhang X, Albright AL, Cowie CC, Klein R, Saaddine JB., Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: implications for diabetes diagnostic thresholds. Diabetes Care 2009 32 2027 2032. doi: 10.2337/dc09-0440
13. Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, Klein R, Klein BE, Zimmet P, Shaw J., Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies [published correction appears in Lancet. 2008;371:1838]. Lancet 2008 371 736 743. doi: 10.1016/S0140-6736(08)60343-8
14. Davidson MB, Schriger DL, Peters AL, Lorber B., Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria [published correction appears in JAMA. 1999;281:2187]. JAMA 1999 281 1203 1210
15. International Expert Committee International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009 32 1327 1334
16. Tsugawa Y, Takahashi O, Meigs JB, Davis RB, Imamura F, Fukui T, Taylor WC, Wee CC., New diabetes diagnostic threshold of hemoglobin A(1c) and the 3-year incidence of retinopathy. Diabetes 2012 61 3280 3284. doi: 10.2337/db12-0103
17. Emerging Risk Factors Collaboration Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, Kaptoge S, Kondapally Seshasai SR, Thompson A, Sarwar N, Willeit P, Ridker PM, Barr EL, Khaw KT, Psaty BM, Brenner H, Balkau B, Dekker JM, Lawlor DA, Daimon M, Willeit J, Njolstad I, Nissinen A, Brunner EJ, Kuller LH, Price JF, Sundstrom J, Knuiman MW, Feskens EJ, Verschuren WM, Wald N, Bakker SJ, Whincup PH, Ford I, Goldbourt U, Gomez-de-la-Camara A, Gallacher J, Simons LA, Rosengren A, Sutherland SE, Bjorkelund C, Blazer DG, Wassertheil-Smoller S, Onat A, Marin IA, Casiglia E, Jukema JW, Simpson LM, Giampaoli S, Nordestgaard BG, Selmer R, Wennberg P, Kauhanen J, Salonen JT, Dankner R, Barrett-Connor E, Kavousi M, Gudnason V, Evans D, Wallace RB, Cushman M, D'Agostino RB Sr, Umans JG, Kiyohara Y, Nakagawa H, Sato S, Gillum RF, Folsom AR, van der Schouw YT, Moons KG, Griffin SJ, Sattar N, Wareham NJ, Selvin E, Thompson SG, Danesh J., Emerging Risk Factors Collaboration Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA 2014 311 1225 1233. doi: 10.1001/jama.2014.1873 Emerging Risk Factors Collaboration
18. Selvin E, Ning Y, Steffes MW, Bash LD, Klein R, Wong TY, Astor BC, Sharrett AR, Brancati FL, Coresh J., Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes 2011 60 298 305. doi: 10.2337/db10-1198
19. Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, Selvin E., The association of hemoglobin A1c with incident heart failure among people without diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 2010 59 2020 2026. doi: 10.2337/db10-0165
20. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL., Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010 362 800 811. doi: 10.1056/NEJMoa0908359
21. Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H, Kodama S, Hsieh SD, Mori Y, Shimano H, Yamada N, Kosaka K, Sone H., HbA1c 5·7-6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet 2011 378 147 155. doi: 10.1016/S0140-6736(11)60472-8
22. Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles MA, Eschwege E, DESIR Study Group Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2006 29 1619 1625. doi: 10.2337/dc05-2525
23. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N., Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004 141 413 420
24. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N., Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001 322 15 18
25. Sarwar N, Aspelund T, Eiriksdottir G, Gobin R, Seshasai SR, Forouhi NG, Sigurdsson G, Danesh J, Gudnason V., Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med 2010 7 e1000278. doi: 10.1371/journal.pmed.1000278
26. Selvin E, Crainiceanu CM, Brancati FL, Coresh J., Short-Term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007 167 1545 1551. doi: 10.1001/archinte.167.14.1545
27. Lacher DA, Hughes JP, Carroll MD., Estimate of biological variation of laboratory analytes based on the Third National Health and Nutrition Examination Survey. Clin Chem 2005 51 450 452. doi: 10.1373/clinchem.2004.039354
28. Emerging Risk Factors Collaboration Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njolstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J., Emerging Risk Factors Collaboration Diabetes mellitus, fasting glucose, and risk of cause-specific death [published correction appears in N Engl J Med. 2011;364:1281]. N Engl J Med 2011 364 829 841. doi: 10.1056/NEJMoa1008862
29. Little RR, Roberts WL., A review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol 2009 3 446 451
30. Sacks DB., A1C versus glucose testing: a comparison. Diabetes Care 2011 34 518 523. doi: 10.2337/dc10-1546
31. Meigs JB, Nathan DM, Cupples LA, Wilson PW, Singer DE., Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. J Clin Epidemiol 1996 49 411 417
32. Selvin E, Steffes MW, Gregg E, Brancati FL, Coresh J., Performance of A1C for the classification and prediction of diabetes. Diabetes Care 2011 34 84 89. doi: 10.2337/dc10-1235
33. Little RR, Rohlfing CL, Sacks DB, National Glycohemoglobin Standardization Program (NGSP) Steering Committee Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 2011 57 205 214. doi: 10.1373/clinchem.2010.148841
34. Look AHEAD Research Group Wadden TA, West DS, Delahanty L, Jakicic J, Rejeski J, Williamson D, Berkowitz RI, Kelley DE, Tomchee C, Hill JO, Kumanyika S., Look AHEAD Research Group The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it [published correction appears in Obesity (Silver Spring). 2007;15:1339]. Obesity (Silver Spring) 2006 14 737 752
35. Dunn AL, Marcus BH, Kampert JB, Garcia ME, Kohl HW 3rd, Blair SN., Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial. JAMA 1999 281 327 334
36. Wadden TA, West DS, Neiberg RH, Wing RR, Ryan DH, Johnson KC, Foreyt JP, Hill JO, Trence DL, Vitolins MZ, Look AHEAD Research Group One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring) 2009 17 713 722. doi: 10.1038/oby.2008.637
37. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ., Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes [published correction appears in N Engl J Med. 2014;370:1866]. N Engl J Med 2013 369 145 154. doi: 10.1056/NEJMoa1212914
38. Gerstein HC., Do lifestyle changes reduce serious outcomes in diabetes? N Engl J Med 2013 369 189 190. doi: 10.1056/NEJMe1306987
39. Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, Mikus CR, Myers V, Nauta M, Rodarte RQ, Sparks L, Thompson A, Earnest CP., Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial [published correction appears in JAMA. 2011;305:892]. JAMA 2010 304 2253 2262. doi: 10.1001/jama.2010.1710
40. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 285 2486 2497
41. American Heart Association Nutrition Committee Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J., American Heart Association Nutrition Committee Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee [published corrections appear Circulation. 2006;114:e629]. Circulation 2006 114 82 96 American Heart Association Nutrition Committee
42. Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB, Horton ES, Ismail-Beigi F, Jellinger PS, Jones KL, Jovanovič L, Lebovitz H, Levy P, Moghissi ES, Orzeck EA, Vinik AI, Wyne KL, AACE Task Force for Developing Diabetes Comprehensive Care Plan American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011 17 suppl 2 1 53
43. Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, Neumiller JJ, Nwankwo R, Verdi CL, Urbanski P, Yancy WS Jr, Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 2014 37 suppl 1 S120 S143. doi: 10.2337/dc14-S120
44. American Diabetes Association Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2007 30 suppl 1 S48 S65
45. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA, PREDIMED Study Investigators Primary prevention of cardiovascular disease with a Mediterranean diet [published correction appears N Engl J Med 2013 368 1279 1290. doi: 10.1056/NEJMoa1200303
46. Anderson JW, Randles KM, Kendall CW, Jenkins DJ., Carbohydrate and fiber recommendations for individuals with diabetes: a quantitative assessment and meta-Analysis of the evidence. J Am Coll Nutr 2004 23 5 17
47. Liu S, Manson JE, Stampfer MJ, Holmes MD, Hu FB, Hankinson SE, Willett WC., Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women. Am J Clin Nutr 2001 73 560 566
48. Levitan EB, Cook NR, Stampfer MJ, Ridker PM, Rexrode KM, Buring JE, Manson JE, Liu S., Dietary glycemic index, dietary glycemic load, blood lipids, and C-reactive protein. Metabolism 2008 57 437 443. doi: 10.1016/j.metabol.2007.11.002
49. Kelly S, Frost G, Whittaker V, Summerbell C., Low glycaemic index diets for coronary heart disease. Cochrane Database Syst Rev 2004 CD004467
50. van Dam RM, Visscher AW, Feskens EJ, Verhoef P, Kromhout D., Dietary glycemic index in relation to metabolic risk factors and incidence of coronary heart disease: the Zutphen Elderly Study. Eur J Clin Nutr 2000 54 726 731
51. Wolever TM, Gibbs AL, Mehling C, Chiasson JL, Connelly PW, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW, Ryan EA., The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. Am J Clin Nutr 2008 87 114 125
52. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, on behalf of the American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011 123 2292 2333. doi: 10.1161/CIR.0b013e3182160726
53. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, Gerstein HC, HOPE Study; MICRO-HOPE Study Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002 25 1919 1927
54. Lichtenstein AH., Nutrients and cardiovascular disease: no easy answers. Curr Opin Lipidol 2005 16 1 3
55. Montori VM, Farmer A, Wollan PC, Dinneen SF., Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 2000 23 1407 1415
56. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M., Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Z Kardiol 2004 93 439 453. doi: 10.1007/s00392-004-0075-3
57. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S., The antioxidant vitamins and cardiovascular disease: a critical review of epidemiologic and clinical trial data. Ann Intern Med 1995 123 860 872
58. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ, Jordan HS, Kendall KA, Lux LJ, Mentor-Marcel R, Morgan LC, Trisolini MG, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF, 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society [published correction appears Circulation 2014 129 suppl 2 S102 S138. doi: 10.1161/01.cir.0000437739.71477.ee
59. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR, Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [published correction appears Diabetes Care 2012 35 1364 1379. doi: 10.2337/dc12-0413
60. Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, Sanchez E, An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published correction appears Hypertension 2014 63 878 885. doi: 10.1161/HYP.0000000000000003
61. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E., 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [published correction appears JAMA 2014 311 507 520. doi: 10.1001/jama.2013.284427
62. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears Circulation 2014 129 suppl 2 S1 S45. doi: 10.1161/01.cir.0000437738.63853.7a
63. Jeffery RW, Wing RR, Thorson C, Burton LR, Raether C, Harvey J, Mullen M., Strengthening behavioral interventions for weight loss: a randomized trial of food provision and monetary incentives. J Consult Clin Psychol 1993 61 1038 1045
64. Wing RR, Jeffery RW, Burton LR, Thorson C, Nissinoff KS, Baxter JE., Food provision vs structured meal plans in the behavioral treatment of obesity. Int J Obes Relat Metab Disord 1996 20 56 62
65. Heymsfield SB, van Mierlo CA, van der Knaap HC, Heo M, Frier HI., Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord 2003 27 537 549. doi: 10.1038/sj.ijo.0802258
66. Lichtman SW, Pisarska K, Berman ER, Pestone M, Dowling H, Offenbacher E, Weisel H, Heshka S, Matthews DE, Heymsfield SB., Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med 1992 327 1893 1898. doi: 10.1056/NEJM199212313272701
67. Burke LE, Wang J, Sevick MA., Self-monitoring in weight loss: a systematic review of the literature. J Am Diet Assoc 2011 111 92 102. doi: 10.1016/j.jada.2010.10.008
68. Butryn ML, Phelan S, Hill JO, Wing RR., Consistent self-monitoring of weight: a key component of successful weight loss maintenance. Obesity (Silver Spring) 2007 15 3091 3096. doi: 10.1038/oby.2007.368
69. Wing RR, Tate DF, Gorin AA, Raynor HA, Fava JL, Machan J., STOP regain: are there negative effects of daily weighing [published correction appears in J Consult Clin Psychol. 2007;75:715]? J Consult Clin Psychol 2007 75 652 656. doi: 10.1037/0022-006X.75.4.652
70. Wing RR, Papandonatos G, Fava JL, Gorin AA, Phelan S, McCaffery J, Tate DF., Maintaining large weight losses: the role of behavioral and psychological factors. J Consult Clin Psychol 2008 76 1015 1021. doi: 10.1037/a0014159
71. Otto AD, Garcia DO, Jakicic JM., Lifestyle intervention strategies to prevent and control type 2 diabetes. Curr Diab Rep 2008 8 407 412
72. Balducci S, Zanuso S, Massarini M, Corigliano G, Nicolucci A, Missori S, Cavallo S, Cardelli P, Alessi E, Pugliese G, Fallucca F, Italian Diabetes Exercise Study (IDES) Group The Italian Diabetes and Exercise Study (IDES): design and methods for a prospective Italian multicentre trial of intensive lifestyle intervention in people with type 2 diabetes and the metabolic syndrome. Nutr Metab Cardiovasc Dis 2008 18 585 595. doi: 10.1016/j.numecd.2007.07.006
73. Balducci S, Zanuso S, Nicolucci A, De Feo P, Cavallo S, Cardelli P, Fallucca S, Alessi E, Fallucca F, Pugliese G, Italian Diabetes Exercise Study (IDES) Investigators Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med 2010 170 1794 1803. doi: 10.1001/archinternmed.2010.380
74. Clair C, Rigotti NA, Porneala B, Fox CS, D'Agostino RB, Pencina MJ, Meigs JB., Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA 2013 309 1014 1021. doi: 10.1001/jama.2013.1644
75. Bray GA, Ryan DH., Medical therapy for the patient with obesity. Circulation 2012 125 1695 1703. doi: 10.1161/CIRCULATIONAHA.111.026567
76. Leslie WS, Hankey CR, Lean ME., Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 2007 100 395 404. doi: 10.1093/qjmed/hcm044
77. Bray GA., A Guide to Obesity and the Metabolic Syndrome: Origins and Treatment 2011 2011 ed Boca Raton, FL CRC Press
78. Bray G, Look M, Ryan D., Treatment of the obese patient in primary care: targeting and meeting goals and expectations. Postgrad Med 2013 125 67 77. doi: 10.3810/pgm.2013.09.2692
79. Ryan DH, Bray GA., Pharmacologic treatment options for obesity: what is old is new again. Curr Hypertens Rep 2013 15 182 189. doi: 10.1007/s11906-013-0343-6
80. Leblanc ES, O'Connor E, Whitlock EP, Patnode CD, Kapka T., Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2011 155 434 447. doi: 10.7326/0003-4819-155-7-201110040-00006
81. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR, Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010 363 245 256. doi: 10.1056/NEJMoa0909809
82. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH., Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012 95 297 308. doi: 10.3945/ajcn.111.024927
83. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E, COR-I Study Group Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published corrections appear in Lancet. 2010;376:594 and Lancet. 2010;376:1392]. Lancet 2010 376 595 605. doi: 10.1016/S0140-6736(10)60888-4
84. Finer N, Ryan DH, Renz CL, Hewkin AC., Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab 2006 8 206 213. doi: 10.1111/j.1463-1326.2005.00481.x
85. Rissanen A, Lean M, Rössner S, Segal KR, Sjöström L., Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord 2003 27 103 109. doi: 10.1038/sj.ijo.0802165
86. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S, Savolainen MJ, Van Gaal L, NN8022-1807 Investigators Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide [published corrections appear in Int J Obes (Lond). 2012;36:890 and Int J Obes (Lond). 2013;37:322]. Int J Obes (Lond) 2012 36 843 854. doi: 10.1038/ijo.2011.158
87. Kim Y, Babu AR., Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012 5 313 327. doi: 10.2147/DMSO.S22545
88. Consensus Development Conference Panel. NIH conference: gastrointestinal surgery for severe obesity. Ann Intern Med 1991 115 956 961
89. Dixon JB, Zimmet P, Alberti KG, Rubino F, International Diabetes Federation Taskforce on Epidemiology and Prevention Bariatric surgery: an IDF statement for obese type 2 diabetes. Diabet Med 2011 28 628 642. doi: 10.1111/j.1464-5491.2011.03306.x
90. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K., Bariatric surgery: a systematic review and meta-Analysis [published correction appears in JAMA. 2005;293:1728]. JAMA 2004 292 1724 1737. doi: 10.1001/jama.292.14.1724
91. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM, Swedish Obese Subjects Study Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007 357 741 752. doi: 10.1056/NEJMoa066254
92. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I., Weight and type 2 diabetes after bariatric surgery: systematic review and meta-Analysis. Am J Med 2009 122 248 256.e5. doi: 10.1016/j.amjmed.2008.09.041
93. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H, Swedish Obese Subjects Study Scientific Group Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004 351 2683 2693. doi: 10.1056/NEJMoa035622
94. Carlsson LM, Peltonen M, Ahlin S, Anveden Å Bouchard C, Carlsson B, Jacobson P, Lönroth H, Maglio C, Näslund I, Pirazzi C, Romeo S, Sjöholm K, Sjöström E, Wedel H, Svensson PA, Sjöström L., Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012 367 695 704. doi: 10.1056/NEJMoa1112082
95. Navaneethan SD, Kelly KR, Sabbagh F, Schauer PR, Kirwan JP, Kashyap SR., Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery. Obes Surg 2010 20 308 315. doi: 10.1007/s11695-009-0026-1
96. Iaconelli A, Panunzi S, De Gaetano A, Manco M, Guidone C, Leccesi L, Gniuli D, Nanni G, Castagneto M, Ghirlanda G, Mingrone G., Effects of bilio-pancreatic diversion on diabetic complications: a 10-year follow-up. Diabetes Care 2011 34 561 567. doi: 10.2337/dc10-1761
97. Vest AR, Heneghan HM, Schauer PR, Young JB., Surgical management of obesity and the relationship to cardiovascular disease. Circulation 2013 127 945 959. doi: 10.1161/CIRCULATIONAHA.112.103275
98. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M., Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008 299 316 323. doi: 10.1001/jama.299.3.316
99. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL., Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012 366 1567 1576. doi: 10.1056/NEJMoa1200225
100. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F., Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012 366 1577 1585. doi: 10.1056/NEJMoa1200111
101. Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ, Leslie DB, Chong K, Jeffery RW, Ahmed L, Vella A, Chuang LM, Bessler M, Sarr MG, Swain JM, Laqua P, Jensen MD, Bantle JP., Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 2013 309 2240 2249. doi: 10.1001/jama.2013.5835
102. Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I., Trends in mortality in bariatric surgery: a systematic review and meta-Analysis. Surgery 2007 142 621 632. doi: 10.1016/j.surg.2007.07.018
103. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium Flum DR, Belle SH, King WC, Wahed AS, Berk P, Chapman W, Pories W, Courcoulas A, McCloskey C, Mitchell J, Patterson E, Pomp A, Staten MA, Yanovski SZ, Thirlby R, Wolfe B., Longitudinal Assessment of Bariatric Surgery (LABS) Consortium Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009 361 445 454. doi: 10.1056/NEJMoa0901836
104. Antithrombotic Trialists' (ATT) Collaboration Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A., Antithrombotic Trialists' (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-Analysis of individual participant data from randomised trials. Lancet 2009 373 1849 1860. doi: 10.1016/S0140-6736(09)60503-1
105. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR., Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-Analysis of randomized trials. Am Heart J 2011 162 115 124.e2. doi: 10.1016/j.ahj.2011.04.006
106. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, Doll R., Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988 296 313 316
107. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989 321 129 135
108. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, PPP Collaborative Group Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003 26 3264 3272
109. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE., A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005 352 1293 1304. doi: 10.1056/NEJMoa050613
110. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998 351 233 241
111. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S., Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet 1998 351 1755 1762
112. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14: ETDRS Investigators. JAMA 1992 268 1292 1300
113. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y, Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial [published corrections appear in JAMA. 2009;301:1882 and JAMA. 2012;308:1861]. JAMA 2008 300 2134 2141. doi: 10.1001/jama.2008.623
114. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R, Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008 337 a1840
115. Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, Wang K, Zou Y, Ge J., Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-Analysis. Diabetes Res Clin Pract 2010 87 211 218. doi: 10.1016/j.diabres.2009.09.029
116. Younis N, Williams S, Ammori B, Soran H., Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-Analysis. Expert Opin Pharmacother 2010 11 1459 1466. doi: 10.1517/14656561003792538
117. Simpson SH, Gamble JM, Mereu L, Chambers T., Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-Analysis. J Gen Intern Med 2011 26 1336 1344. doi: 10.1007/s11606-011-1757-y
118. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS., Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010 121 2694 2701. doi: 10.1161/CIR.0b013e3181e3b133
119. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, Nicolucci A., Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-Analysis of randomised controlled trials [published correction appears in BMJ. 2010;340:c374]. BMJ 2009 339 b4531. doi: 10.1136/bmj.b4531
120. Calvin AD, Aggarwal NR, Murad MH, Shi Q, Elamin MB, Geske JB, Fernandez-Balsells MM, Albuquerque FN, Lampropulos JF, Erwin PJ, Smith SA, Montori VM., Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-Analysis comparing patients with and without diabetes. Diabetes Care 2009 32 2300 2306. doi: 10.2337/dc09-1297
121. Pignone M, Earnshaw S, Tice JA, Pletcher MJ., Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006 144 326 336
122. Pignone M, Earnshaw S, Pletcher MJ, Tice JA., Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med 2007 167 290 295. doi: 10.1001/archinte.167.3.290
123. Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG, ACCORD Study Group Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007 99 4i 20i. doi: 10.1016/j.amjcard.2007.03.002
124. Emerging Risk Factors Collaboration Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J., Emerging Risk Factors Collaboration Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-Analysis of 102 prospective studies [published correction appears in Lancet. 2010;376:958]. Lancet 2010 375 2215 2222. doi: 10.1016/S0140-6736(10)60484-9
125. Anand SS, Dagenais GR, Mohan V, Diaz R, Probstfield J, Freeman R, Shaw J, Lanas F, Avezum A, Budaj A, Jung H, Desai D, Bosch J, Yusuf S, Gerstein HC, EpiDREAM Investigators Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Prev Cardiol 2012 19 755 764. doi: 10.1177/1741826711409327
126. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH., Meta-Analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004 141 421 431
127. Gerstein HC, Islam S, Anand S, Almahmeed W, Damasceno A, Dans A, Lang CC, Luna MA, McQueen M, Rangarajan S, Rosengren A, Wang X, Yusuf S., Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia 2010 53 2509 2517. doi: 10.1007/s00125-010-1871-0
128. Gerstein HC, Pogue J, Mann JF, Lonn E, Dagenais GR, McQueen M, Yusuf S, HOPE Investigators The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005 48 1749 1755. doi: 10.1007/s00125-005-1858-4
129. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 321 405 412
130. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet 1998 352 837 853
131. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 2643 2653. doi: 10.1056/NEJMoa052187
132. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA., 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 1577 1589. doi: 10.1056/NEJMoa0806470
133. Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P., Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-Analysis of randomized trials. Am Heart J 2006 152 27 38. doi: 10.1016/j.ahj.2005.09.015
134. Action to Control Cardiovascular Risk in Diabetes Study Group Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT., Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 358 2545 2559. doi: 10.1056/NEJMoa0802743
135. ADVANCE Collaborative Group Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F., ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 358 2560 2572. doi: 10.1056/NEJMoa0802987
136. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators Glucose control and vascular complications in veterans with type 2 diabetes [published correction appears in N Engl J Med. 2009;361:1028]. N Engl J Med 2009 360 129 139. doi: 10.1056/NEJMoa0808431
137. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS, American Diabetes Association; American College of Cardiology Foundation; American Heart Association Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association [published correction appears in Circulation. 2009;119:e605]. Circulation 2009 119 351 357. doi: 10.1161/CIRCULATIONAHA.108.191305
138. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME., The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010 340 b4909. doi: 10.1136/bmj.b4909
139. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC Jr, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER, Action to Control Cardiovascular Risk in Diabetes Investigators Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010 33 983 990. doi: 10.2337/dc09-1278
140. Duckworth WC, Abraira C, Moritz TE, Davis SN, Emanuele N, Goldman S, Hayward R, Huang GD, Marks JB, Reaven PD, Reda DJ, Warren SR, Zieve FJ, Investigators of the VADT The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications 2011 25 355 361. doi: 10.1016/j.jdiacomp.2011.10.003
141. Control Group Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M., Control Group Intensive glucose control and macrovascular outcomes in type 2 diabetes [published correction appears in Diabetologia. 2009;52:2470]. Diabetologia 2009 52 2288 2298
142. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N., Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-Analysis of randomised controlled trials. Lancet 2009 373 1765 1772. doi: 10.1016/S0140-6736(09)60697-8
143. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J., Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009 151 394 403
144. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C., Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-Analysis of randomised controlled trials. BMJ 2011 343 d4169. doi: 10.1136/bmj.d4169
145. ORIGIN Trial Investigators Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, Yusuf S., ORIGIN Trial Investigators Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012 367 319 328. doi: 10.1056/NEJMoa1203858
146. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S., Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011 154 554 559. doi: 10.7326/0003-4819-154-8-201104190-00007
147. Lamanna C, Monami M, Marchionni N, Mannucci E., Effect of metformin on cardiovascular events and mortality: a meta-Analysis of randomized clinical trials. Diabetes Obes Metab 2011 13 221 228. doi: 10.1111/j.1463-1326.2010.01349.x
148. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S., Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations [published correction appears in Ann Intern Med. 2011;155:67-68]. Ann Intern Med 2011 154 602 613. doi: 10.7326/0003-4819-154-9-201105030-00336
149. Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, Zhou Z, Tang W, Zhao J, Cui L, Zou D, Wang D, Li H, Liu C, Wu G, Shen J, Zhu D, Wang W, Shen W, Ning G, SPREAD-DIMCAD Investigators Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013 36 1304 1311. doi: 10.2337/dc12-0719
150. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive Investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366 1279 1289. doi: 10.1016/S0140-6736(05)67528-9
151. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA, PROactive Investigators Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007 30 2773 2778. doi: 10.2337/dc07-0717
152. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, RECORD Study Team Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009 373 2125 2135. doi: 10.1016/S0140-6736(09)60953-3
153. Hiatt WR, Kaul S, Smith RJ., The cardiovascular safety of diabetes drugs: insights from the rosiglitazone experience. N Engl J Med 2013 369 1285 1287. doi: 10.1056/NEJMp1309610
154. Nissen SE, Wolski K., Rosiglitazone revisited: an updated meta-Analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010 170 1191 1201. doi: 10.1001/archinternmed.2010.207
155. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002 359 2072 2077. doi: 10.1016/S0140-6736(02)08905-5
156. Joffe HV, Parks MH, Temple R., Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus. Rev Endocr Metab Disord 2010 11 21 30. doi: 10.1007/s11154-010-9130-8
157. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013 369 1317 1326. doi: 10.1056/NEJMoa1307684
158. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013 369 1327 1335. doi: 10.1056/NEJMoa1305889
159. Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, Wexler D, Lachin JM, GRADE Study Research Group Rationale and design of the Glycemia Reduction Approaches in Diabetes: a comparative effectiveness study (GRADE). Diabetes Care 2013 36 2254 2261. doi: 10.2337/dc13-0356
160. Cryer PE., The barrier of hypoglycemia in diabetes. Diabetes 2008 57 3169 3176. doi: 10.2337/db08-1084
161. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, Leese GP, DARTS/MEMO Collaboration Frequency and predictors of hypoglycaemia in type 1 and insulin-Treated type 2 diabetes: a population-based study. Diabet Med 2005 22 749 755. doi: 10.1111/j.1464-5491.2005.01501.x
162. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007 50 1140 1147
163. Cryer PE., Diverse causes of hypoglycemia-Associated autonomic failure in diabetes. N Engl J Med 2004 350 2272 2279. doi: 10.1056/NEJMra031354
164. Cryer PE., Severe hypoglycemia predicts mortality in diabetes. Diabetes Care 2012 35 1814 1816. doi: 10.2337/dc12-0749
165. Yakubovich N, Gerstein HC., Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation 2011 123 342 348. doi: 10.1161/CIRCULATIONAHA.110.948489
166. Frier BM, Schernthaner G, Heller SR., Hypoglycemia and cardiovascular risks. Diabetes Care 2011 34 suppl 2 S132 S137. doi: 10.2337/dc11-s220
167. Gill GV, Woodward A, Casson IF, Weston PJ., Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes: the "dead in bed" syndrome revisited. Diabetologia 2009 52 42 45. doi: 10.1007/s00125-008-1177-7
168. Desouza CV, Bolli GB, Fonseca V., Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010 33 1389 1394. doi: 10.2337/dc09-2082
169. Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R., Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes 2009 58 360 366. doi: 10.2337/db08-1153
170. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, Childress RD, Craven TE, Cuddihy RM, Dailey G, Feinglos MN, Ismail-Beigi F, Largay JF, O'Connor PJ, Paul T, Savage PJ, Schubart UK, Sood A, Genuth S, ACCORD Investigators The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010 340 b5444. doi: 10.1136/bmj.b5444
171. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S, ADVANCE Collaborative Group Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010 363 1410 1418. doi: 10.1056/NEJMoa1003795
172. Seaquist ER, Miller ME, Bonds DE, Feinglos M, Goff DC Jr, Peterson K, Senior P, ACCORD Investigators The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care 2012 35 409 414. doi: 10.2337/dc11-0996
173. Deedwania PC., Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. Cardiol Clin 2005 23 139 152. doi: 10.1016/j.ccl.2004.06.006
174. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA. 2003;290:197]. JAMA 2003 289 2560 2572. doi: 10.1001/jama.289.19.2560
175. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 [published correction appears in BMJ. 1999;318:29]. BMJ 1998 317 703 713
176. ACCORD Study Group Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F., ACCORD Study Group Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 362 1575 1585. doi: 10.1056/NEJMoa1001286
177. Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B., Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007 370 829 840. doi: 10.1016/S0140-6736(07)61303-8
178. Bangalore S, Kumar S, Lobach I, Messerli FH., Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-Analyses of randomized trials. Circulation 2011 123 2799 2810. doi: 10.1161/CIRCULATIONAHA.110.016337
179. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S, ONTARGET Investigators Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009 27 1360 1369. doi: 10.1097/HJH.0b013e32832d7370
180. Deedwania PC., Blood pressure control in diabetes mellitus: is lower always better, and how low should it go? Circulation 2011 123 2776 2778. doi: 10.1161/CIRCULATIONAHA.111.033704
181. Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, Macmahon S, Neal B, PROGRESS Collaborative Group Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006 24 1201 1208. doi: 10.1097/01.hjh.0000226212.34055.86
182. Soran H, Durrington PN., Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol 2011 22 254 261. doi: 10.1097/MOL.0b013e328348a43f
183. Koska J, Saremi A, Bahn G, Yamashita S, Reaven PD, Veterans Affairs Diabetes Trial Investigators The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2013 36 2408 2414. doi: 10.2337/dc12-2082
184. Cholesterol Treatment Trialists' (CTT) Collaborators Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C., Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-Analysis. Lancet 2008 371 117 125. doi: 10.1016/S0140-6736(08)60104-X
185. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW., Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002 162 2597 2604
186. Bezafibrate Infarction Prevention (BIP) Study Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000 102 21 27
187. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD Study Investigators Effects of long-Term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial [published correction appears Lancet 2005 366 1849 1861. doi: 10.1016/S0140-6736(05)67667-2
188. ACCORD Study Group Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP., ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus [published correction appears in N Engl J Med. 2010;362:1748]
189. AIM-HIGH Investigators Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W., AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy [published correction appears N Engl J Med 2011 365 2255 2267. doi: 10.1056/NEJMoa1107579
190. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 367 2089 2099. doi: 10.1056/NEJMoa1206797
191. Rubin RR, Peyrot M, Gaussoin SA, Espeland MA, Williamson D, Faulconbridge LF, Wadden TA, Ewing L, Safford M, Evans-Hudnall G, Wing RR, Knowler WC, Look AHEAD Research Group Four-year analysis of cardiovascular disease risk factors, depression symptoms, and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetes Care 2013 36 1088 1094. doi: 10.2337/dc12-1871
192. KDOQI KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007 49 suppl 2 S12 S154
193. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, de Jong PE, Griffith KE, Hemmelgarn BR, Iseki K, Lamb EJ, Levey AS, Riella MC, Shlipak MG, Wang H, White CT, Winearls CG., Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013 3 1 150
194. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J., Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011 305 2532 2539. doi: 10.1001/jama.2011.861
195. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, de Jong PE, Wen CP, Nelson RG, Chronic Kidney Disease Prognosis Consortium Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-Analysis [published correction appears in Lancet. 2013;381:374]. Lancet 2012 380 1662 1673. doi: 10.1016/S0140-6736(12)61350-6
196. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH., Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013 24 302 308. doi: 10.1681/ASN.2012070718
197. Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ., Chronic kidney disease stages 1-3: screening, monitoring, and treatment. AHRQ Comparative Effectiveness Reviews 2012 11 EHC075-EF
198. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 345 851 860. doi: 10.1056/NEJMoa011303
199. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 345 861 869. doi: 10.1056/NEJMoa011161
200. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy [published correction appears in N Engl J Med. 2005;352:1731]. N Engl J Med 2004 351 1952 1961. doi: 10.1056/NEJMoa042274
201. Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J., Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-Analysis. JAMA Intern Med 2014 174 773 785. doi: 10.1001/jamainternmed.2014.348
202. National Kidney Foundation KDOQI clinical practice guideline for diabetes and CKD: 2012 update [published correction appears in Am J Kidney Dis. 2013;61:1049]. Am J Kidney Dis 2012 60 850 886. doi: 10.1053/j.ajkd.2012.07.005
203. Kunz R, Friedrich C, Wolbers M, Mann JF., Meta-Analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008 148 30 48
204. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET Investigators Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008 372 547 553. doi: 10.1016/S0140-6736(08)61236-2
205. Upchurch CT, Barrett EJ., Clinical review: screening for coronary artery disease in type 2 diabetes. J Clin Endocrinol Metab 2012 97 1434 1442. doi: 10.1210/jc.2011-2122
206. Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ, ADA Screening for coronary artery disease in patients with diabetes. Diabetes Care 2007 30 2729 2736. doi: 10.2337/dc07-9927
207. Davis TM, Coleman RL, Holman RR, UKPDS Group Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79. Circulation 2013 127 980 987. doi: 10.1161/CIRCULATIONAHA.112.000908
208. Scheidt-Nave C, Barrett-Connor E, Wingard DL., Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with non-insulin-dependent diabetes mellitus in a defined population. Circulation 1990 81 899 906
209. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010 122 e584 e636. doi: 10.1161/CIR.0b013e3182051b4c
210. Rajagopalan N, Miller TD, Hodge DO, Frye RL, Gibbons RJ., Identifying high-risk asymptomatic diabetic patients who are candidates for screening stress single-photon emission computed tomography imaging. J Am Coll Cardiol 2005 45 43 49. doi: 10.1016/j.jacc.2004.06.078
211. Doobay AV, Anand SS., Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol 2005 25 1463 1469. doi: 10.1161/01.ATV.0000168911.78624.b7
212. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am J Cardiol 1997 79 134 139
213. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE, DIAD Investigators Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009 301 1547 1555. doi: 10.1001/jama.2009.476
214. Lièvre MM, Moulin P, Thivolet C, Rodier M, Rigalleau V, Penfornis A, Pradignac A, Ovize M, DYNAMIT Investigators Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-Analysis assessing the effectiveness of systematic screening. Trials 2011 12 23. doi: 10.1186/1745-6215-12-23
215. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Heller GV, Filipchuk N, Engel S, Ratner RE, Iskandrian AE, Detection of Ischemia in Asymptomatic Diabetics Investigators Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study [published correction appears in Diabetes Care. 2005;28:504]. Diabetes Care 2004 27 1954 1961
216. Nasir K, Rubin J, Blaha MJ, Shaw LJ, Blankstein R, Rivera JJ, Khan AN, Berman D, Raggi P, Callister T, Rumberger JA, Min J, Jones SR, Blumenthal RS, Budoff MJ., Interplay of coronary artery calcification and traditional risk factors for the prediction of all-cause mortality in asymptomatic individuals. Circ Cardiovasc Imaging 2012 5 467 473. doi: 10.1161/CIRCIMAGING.111.964528
217. Wong ND, Nelson JC, Granston T, Bertoni AG, Blumenthal RS, Carr JJ, Guerci A, Jacobs DR Jr, Kronmal R, Liu K, Saad M, Selvin E, Tracy R, Detrano R., Metabolic syndrome, diabetes, and incidence and progression of coronary calcium: the Multiethnic Study of Atherosclerosis study. JACC Cardiovasc Imaging 2012 5 358 366. doi: 10.1016/j.jcmg.2011.12.015
218. Malik S, Budoff MJ, Katz R, Blumenthal RS, Bertoni AG, Nasir K, Szklo M, Barr RG, Wong ND., Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome and diabetes: the Multi-Ethnic Study of Atherosclerosis. Diabetes Care 2011 34 2285 2290. doi: 10.2337/dc11-0816
219. Elkeles RS, Godsland IF, Feher MD, Rubens MB, Roughton M, Nugara F, Humphries SE, Richmond W, Flather MD, PREDICT Study Group Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. Eur Heart J 2008 29 2244 2251. doi: 10.1093/eurheartj/ehn279
220. Agarwal S, Morgan T, Herrington DM, Xu J, Cox AJ, Freedman BI, Carr JJ, Bowden DW., Coronary calcium score and prediction of all-cause mortality in diabetes: the Diabetes Heart Study. Diabetes Care 2011 34 1219 1224. doi: 10.2337/dc11-0008
221. Scholte AJ, Schuijf JD, Kharagjitsingh AV, Jukema JW, Pundziute G, van der Wall EE, Bax JJ., Prevalence of coronary artery disease and plaque morphology assessed by multi-slice computed tomography coronary angiography and calcium scoring in asymptomatic patients with type 2 diabetes. Heart 2008 94 290 295. doi: 10.1136/hrt.2007.121921
222. Hoff JA, Quinn L, Sevrukov A, Lipton RB, Daviglus M, Garside DB, Ajmere NK, Gandhi S, Kondos GT., The prevalence of coronary artery calcium among diabetic individuals without known coronary artery disease. J Am Coll Cardiol 2003 41 1008 1012
223. Scholte AJ, Bax JJ, Wackers FJ., Screening of asymptomatic patients with type 2 diabetes mellitus for silent coronary artery disease: combined use of stress myocardial perfusion imaging and coronary calcium scoring. J Nucl Cardiol 2006 13 11 18. doi: 10.1016/j.nuclcard.2005.11.002
224. Schurgin S, Rich S, Mazzone T., Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care 2001 24 335 338
225. Raggi P, Shaw LJ, Berman DS, Callister TQ., Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol 2004 43 1663 1669. doi: 10.1016/j.jacc.2003.09.068
226. Kondola S, Davis WA, Dembo LG, Davis TM., A cardiac magnetic resonance imaging study of electrocardiographic Q waves in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract 2008 82 87 92. doi: 10.1016/j.diabres.2008.06.016
227. Anand DV, Lim E, Hopkins D, Corder R, Shaw LJ, Sharp P, Lipkin D, Lahiri A., Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J 2006 27 713 721. doi: 10.1093/eurheartj/ehi808
228. Bybee KA, Lee J, Markiewicz R, Longmore R, McGhie AI, O'Keefe JH, Hsu BL, Kennedy K, Thompson RC, Bateman TM., Diagnostic and clinical benefit of combined coronary calcium and perfusion assessment in patients undergoing PET/CT myocardial perfusion stress imaging. J Nucl Cardiol 2010 17 188 196. doi: 10.1007/s12350-009-9159-9
229. Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD., Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial [published correction appears in J Am Coll Cardiol. 2011;58:1832]. J Am Coll Cardiol 2005 46 166 172. doi: 10.1016/j.jacc.2005.02.089
230. Muhlestein JB, Lappé DL, Lima JA, Rosen BD, May HT, Knight S, Bluemke DA, Towner SR, Le V, Bair TL, Vavere AL, Anderson JL., Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA 2014 312 2234 2243. doi: 10.1001/jama.2014.15825
231. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles WH, Capewell S., Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007 356 2388 2398. doi: 10.1056/NEJMsa053935
232. Gore MO, Patel MJ, Kosiborod M, Parsons LS, Khera A, de Lemos JA, Rogers WJ, Peterson ED, Canto JC, McGuire DK, National Registry of Myocardial Infarction Investigators Diabetes mellitus and trends in hospital survival after myocardial infarction, 1994 to 2006: data from the National Registry of Myocardial Infarction. Circ Cardiovasc Qual Outcomes 2012 5 791 797. doi: 10.1161/CIRCOUTCOMES.112.965491